Abstract
In stark contrast to the rest of the pharmaceutical industry, the world market
for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and
visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS
NOW. Order a copy of visiongain' s new report to get the details.
Having grown 16.5 per cent from 2004' s revenues, double-digit growth of the
market will continue to the end of the decade. You need to be aware of how you
can succeed in this area. 1 report will tell you all you need to know. SO
order this report NOW.
- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics
Designed as an essential business aid, The Global Biotech Report 2006 provides
the leading thorough evaluation of your market.
The report provides you with in-depth market analysis for all top-selling
current and major potential products to arrive before the decade ends. The
report extensively identifies biopharmaceuticals market potential by analysing
the latest clinical trial research. The study also examines the challenges
faced by potential biotech companies and opportunities newcomers to the arena.
This is the industry' s premier report. Numbers are strictly limited, so order
today.
Five key questions this report answer' s are:
- 1. What are the market values of the major therapeutic areas of the global
biopharmaceutical market by product from, 2005 to 2011?
- 2. Who are the major companies involved in the world market today and in
the future, and will they be competition to you?
- 3. How imminent are biogenerics and what is their potential market value?
- 4. What strategies can be used to maximise your profits in terms of the
major challenges facing biotech?
- 5. What' s in the 2006 biopharmaceutical pipeline and what revenues can
they reach by 2011?
Due to visiongain' s targeted consultancy work in the area, only a strict 20
copies of the report are issued. Please order your copy now so as you do not
miss out. Copies will be reserved on a strictly first-come-first-serve basis.
So please contact us now.
This report is a vital addition to gaining an understanding of this highly
profitable market sector and will give your company ' the edge' of your
competitors. You can not afford to be without this report from visiongain.
| 
View Cart
